| 1 |
Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures [J]. J Bone Miner Res, 2005, 20(7): 1185-1194.
|
| 2 |
Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) [J]. Arch Osteoporos, 2011, 6: 59-155.
|
| 3 |
张智海，张智若，刘忠厚,等.中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究[J].中国骨质疏松杂志, 2016, 22(1): 1-8.
|
| 4 |
Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease [J]. Endocr Rev, 1986, 7(4): 379-408.
|
| 5 |
Cosman F, De Beur SJ, Leboff MS, et al. Clinician's guide to prevention and treatment of osteoporosis [J]. Osteoporos Int, 2014, 25(10): 2359-2381.
|
| 6 |
Holick MF. Vitamin D deficiency [J]. N Engl J Med, 2007, 357(3): 266-281.
|
| 7 |
Larsen ER, Mosekilde L, Foldspang A. Vitamin D and Calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: A pragmatic population-based 3-year intervention study [J]. J Bone Miner Res, 2004, 19(3): 370-378.
|
| 8 |
Langdahl BL, Harsløf T. Medical treatment of osteoporotic vertebral fractures [J]. Ther Adv Musculoskelet Dis, 2011, 3(1): 17-29.
|
| 9 |
Fleisch H, Russell RG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution [J]. Calcif Tissue Res, 1968, 2(1): Suppl:10-Suppl10a.
|
| 10 |
Reitsma PH, Teitelbaum SL, Bijvoet OL, et al. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro [J]. J Clin Invest, 1982, 70(5): 927-933.
|
| 11 |
张禄锴，马剑雄，李风波,等.双膦酸盐类药物治疗骨质疏松症的研究进展[J].中华老年骨科与康复电子杂志, 2017, 3(3): 184-187.
|
| 12 |
Paskins Z, Warburton L. Bisphosphonates beyond five years [J]. BMJ, 2016, 352: i264.
|
| 13 |
Blum L, Cummings K, Goulet JA, et al. Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management [J]. Eur J Orthop Surg Traumatol, 2016, 26(4): 371-377.
|
| 14 |
Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
|
| 15 |
Bonomi M, Nortilli R, Molino A, et al. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis [J]. Med Oncol, 2010, 27(2): 224-229.
|
| 16 |
Lam J. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand speci city [J]. J Clin Invest, 2001, 108(7): 971-979.
|
| 17 |
Rossini M, Adami G, Adami S, et al. Safety issues and adverse reactions with osteoporosis management [J]. Expert Opin Drug Saf, 2016, 15(3): 321-332.
|
| 18 |
Lacey DL, Boyle WJ, Simonet W, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab [J]. Nat Rev Drug Discov, 2012, 11(5): 401-U150.
|
| 19 |
Papapoulos S. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis:results from the FREEDOM Extension study [J]. Osteoporos Int, 2015, 26(12): 2773-2783.
|
| 20 |
Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [J]. N Engl J Med, 2009, 361(8): 756-765.
|
| 21 |
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [J]. JAMA, 1999, 281(23): 2189-2197.
|
| 22 |
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density,serum cholesterol concentrations,and uterine endometrium in postmenopausal women [J]. N Engl J Med, 1997, 337(23): 1641-1647.
|
| 23 |
Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation [J]. Obstet Gynecol, 2004, 104(4): 837-844.
|
| 24 |
Malozowski S. Lasofoxifene for postmenopausal women with osteoporosis [J]. N Engl J Med, 2010, 362(23): 2227.
|
| 25 |
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis [J]. N Engl J Med, 2001, 344(19): 1434-1441.
|
| 26 |
Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis [J]. N Engl J Med, 2007, 357(20): 2028-2039.
|
| 27 |
Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial [J]. JAMA, 2016, 316(7): 722-733.
|
| 28 |
Meunier PJ, Roux C, Seeman E, et al. The effects of Strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis [J]. N Engl J Med, 2004, 350(5): 459-468.
|
| 29 |
Bonnelye E, Chabadel A, Saltel F, et al. Dual effect of Strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro [J]. Bone, 2008, 42(1): 129-138.
|
| 30 |
Marie PJ. Optimizing bone metabolism in osteoporosis:insight into the pharmacologic profile of Strontium ranelate [J]. Osteoporos Int, 2003, 14(3): 9-12.
|
| 31 |
Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert [J]. Osteoporos Int, 2008, 19(12): 1811-1812.
|
| 32 |
Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database [J]. Osteoporos In, 2010, 21(7): 1181-1187.
|
| 33 |
Jiang Y, Zhang ZL, Zhang ZL, et al. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial [J]. Clin Interv Aging, 2014, 9: 121-127.
|
| 34 |
韩阳，李傲航，叶卫丰. 2型糖尿病并发骨质疏松与NLR、RDW和MPV的关系[J].临床和实验医学杂志, 2017, 16(17): 1734-1736.
|
| 35 |
Mahdiniae DA, Menaquinone-7 OA. (vitamin K2): a new perspective [J]. World J Microbiol Biotechnol, 2017, 33(1): 2.
|
| 36 |
Kodama Y, Okamoto Y, Kubota T, et al. Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy [J]. Brain Dev, 2017, 39(10): 846-850.
|
| 37 |
Xu T, Wang L, Tao Y, et al. The function of naringin in inducing secretion of osteoprotegerin and inhibiting formation of osteoclasts [J]. Evid Based Complement Alternat Med, 2016: 8981650.
|
| 38 |
Zhu HM, Qin L, Garnero P, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis [J]. Bone, 2010, 47(3): S457-S458.
|
| 39 |
Liu M, Zhong C, He RX, et al. Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis [J]. Chin Med J(Engl), 2012, 125(10): 1784-1789.
|
| 40 |
Ouyang L, Zhang QF, Ruan XZ, et al. Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo [J]. Exp Ther Med, 2014, 7(6): 1687-1690.
|
| 41 |
Shuai B, Shen L, Zhu R, et al. Effect of Qing'e formula on the in vitro differentiation of bone marrow-derived mesenchymal stem cells from proximal femurs of postmenopausal osteoporotic mice [J]. BMC Complement Altern Med, 2015, 15: 250.
|
| 42 |
Nelson ER, Wardell SE, Mcdonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis [J]. Bone, 2013, 53(1): 42-50.
|
| 43 |
Xu XH, Dong SS, Guo Y, et al. Molecular Genetic Studies of Gene Identification for Osteoporosis: The 2009 Update [J]. Endocr Rev, 2010, 31(4): 447-505.
|
| 44 |
Liu YZ, Liu YJ, Recker RR, et al. Molecular studies of identification of genes for osteoporosis: The 2002 update [J]. J Endocrinol, 2003, 177(2): 147-196.
|
| 45 |
Liu YJ, Shen H, Xiao P, et al. Molecular Genetic Studies of Gene Identification for Osteoporosis: a 2004 Update [J]. J Bone Miner Res, 2006, 21(10):1511-1535.
|